Which manufacturer does Selumetinib come from?

AstraZeneca USA and MSD Inc. (known as Merck & Co. in the United States and Canada) announced in April 2020 that the U.S. Food and Drug Administration (FDA) has approved the kinase inhibitor selumetinib ) For the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who also have symptomatic, inoperable plexiform neurofibromas (PN), trade name Koselugo, which is the world's first regulatory approval for the treatment of NF1 Drugs of PN.1.

NeurofibromatosisType 1 is a rare and debilitating genetic disease. Approximately 30-50% of patients with Neurofibromatosis Type 1 experience plexiform neurofibromas, tumors that grow within the nerve sheath. These plexiform neurofibromascan cause clinical problems such as pain, motor dysfunction, airway dysfunction, bowel/bladder dysfunction, and disfigurement. Results from clinical studies showed that in pediatric patients with NF1 PN who received selumetinib twice daily as oral monotherapy, the overall response rate (ORR) was 66% (33 of 50 patients, confirmed partial response).

SelumetinibThe original drug has been launched in China, but it has not yet entered the scope of medical insurance. SpecificationThe price of 10mg*60 tablets per box may be more than 20,000 yuan, which is relatively expensive. SelumetinibOriginal drug marketed overseas, the price of 10mg*60 pills per box may be more than 50,000 yuan, and the price of 25mg*60 pills per box may be 1 More than RMB 00,000 (the price may fluctuate due to the exchange rate). The ingredients of the original version of selumetinib sold at home and abroad are basically the same. There is currently no generic version of selumetinib on the market. For more drug information and specific prices, please consult Yaode Medical Consultants.